Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17714544 | 0.95 | HPGD (0.39) | USP2SMN1; SMN2PKMGPR119EPHX2 | |
| SCHEMBL16433062 | 0.89 | USP2 (0.40) | USP2SMN1; SMN2PKMGPR119EPHX2 | |
| SCHEMBL17714546 | 0.85 | HPGD (0.38) | USP2SMN1; SMN2PKMGPR119EPHX2 | |
| SCHEMBL4302097 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2PKMGPR119EPHX2 | |
| SCHEMBL17714571 | 0.83 | USP2 (0.42) | USP2SMN1; SMN2PKMGPR119EPHX2 | |
| SCHEMBL27742523 | 0.83 | USP2 (0.44) | USP2SMN1; SMN2PKMGPR119EPHX2 | |
| SCHEMBL5896147 | 0.82 | USP2 (0.49) | USP2SMN1; SMN2PKMGPR119EPHX2 | |
| SCHEMBL25986200 | 0.81 | USP2 (0.45) | USP2SMN1; SMN2GPR119EPHX2EPHX1 | |
| SCHEMBL17714548 | 0.81 | USP2 (0.40) | USP2SMN1; SMN2PKMGPR119EPHX2 | |
| SCHEMBL2604311 | 0.81 | PKM (0.47) | USP2SMN1; SMN2PKMGPR119EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020200314-A1 | NITROGEN-CONTAINING SPIRO DERIVATIVE AS RET INHIBITOR | 南京明德新药研发有限公司 | 2020-10-08 | — | — | WO | disclosed |
| EP-3250204-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-3212618-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3027625-B1 | SPIRO-FUSED DERIVATIVES OF PIPERIDINE USEFUL FOR THE TREATMENT OF INTER ALIA HYPERTENSION AND ACUTE OR CHRONIC HEART FAILURE | MERCK SHARP & DOHME (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180009807-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2018-01-11 | — | — | US | disclosed |
| US-9850245-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850245-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2017-12-26 | — | — | US | disclosed |
| EP-3250204-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170275283-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2017-09-28 | — | — | US | disclosed |
| US-20170275283-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2017-09-28 | — | — | US | disclosed |
| WO-2016065602-A1 | INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016065602-A1 | INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016065582-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016069430-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016069426-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2015017305-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP (US) | 2015-02-05 | — | — | WO | disclosed |
| EP-2481735-A1 | Substituted heterocyclic derivatives and compositions and their pharmaceutical use as antibacterials | Pfizer Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2012-03-15 | — | — | US | disclosed |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | PFIZER INC. | 2011-04-21 | — | — | US | disclosed |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | PFIZER INC | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009807-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | USP2 4810/4885SMN1; SMN2 1726/4885PKM 491/4885 |
| US-20120065188-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | USP2 3872/4885SMN1; SMN2 4085/4885PKM 806/4885 |
| US-20170275283-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | USP2 4805/4885SMN1; SMN2 1659/4885PKM 487/4885 |
| US-20080280879-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS | XDH, CYP2D6, F12 | USP2 3872/4885SMN1; SMN2 4085/4885PKM 806/4885 |
| US-20110092480-A1 | Substituted Heterocyclic Derivatives and Their Pharmaceutical Use and Compositions | XDH, CYP2D6, F12 | USP2 3872/4885SMN1; SMN2 4085/4885PKM 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.